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Background: Quantifying physical activity in chronic obstructive pulmonary disease (COPD) 
is important as physical inactivity is related to poor health outcomes. This study analyzed the 
relationship between patients’ self-reported daily walking time and relevant characteristics 
related to COPD severity.
Methods: Pooled analysis was performed on data from four observational studies on which 
daily walking time was gathered from a personal interview. Patients were classified as physi-
cally inactive if walking time was ,30 min/day. Walking times were described and compared 
according to several markers of disease severity.
Results: The mean daily walking time of 5,969 patients was 66 (standard deviation 
[SD] 47) min/day; 893 (15%) patients were inactive. A linear dose–response relationship was 
observed between walking time and the modified Medical Research Council (mMRC) dyspnea 
score, admissions, COPD assessment test (CAT), body mass index, airway obstruction, dyspnea, 
exacerbation (BODEx) index, and Charlson index (P,0.001). Daily walking times were lower 
in patients classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) B and 
D (P,0.001). Often, inactive patients had mMRC or Charlson index .3, post-bronchodilator 
forced expiratory volume in the first second ,30% predicted, at least one hospitalization for 
COPD, classified as GOLD B or D, BODEx .4, and CAT score .30.
Conclusion: Lower self-reported walking times are related to worse markers of disease 
severity in COPD.
Keywords: COPD, physical activity, symptoms
Introduction
COPD has several significant extra-pulmonary effects, such as skeletal muscle 
impairment and exercise intolerance, which have an important effect on the daily life 
activities of patients with this disease.1,2 This observation is consistent with the fact 
that patients with COPD have significantly lower levels of physical activity compared 
with healthy controls.3 Moreover, reduced levels of physical activity have been found 
to be related to an increased risk of hospital admissions and mortality in COPD.4–6 
Therefore, quantification of physical activity is of great value in these patients.
It has recently been recommended that evaluation of the level of physical activity 
in COPD should be carried out using movement sensors, which constitute portable 
equipment that quantify the activity performed by an individual during a given period of 
time.7 The physical activity of patients with COPD can also be assessed using validated 
questionnaires, which are less expensive and easier to use than movement sensors, 
but most of these questionnaires are still time-consuming.7,8 Thus, these instruments 
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are not feasible in clinical practice. Nonetheless, national 
and international guidelines on the management of COPD 
recommend evaluation and, if necessary, interventions to 
promote physical activity in these patients which has led to 
the need for less sophisticated tools to determine the daily 
physical activity of patients with COPD.1–9
The American College of Sports Medicine recommends 
that older adults should perform at least 30 min of physical 
activity of moderate intensity, such as walking, most days 
of the week in order to maintain or develop fitness.10 Thus, 
individuals not fulfilling this recommendation are cur-
rently considered to be physically inactive. Self-reporting 
of walking time by patients would allow easy data collec-
tion at all levels of care and could help clinicians to better 
understand the impact of the disease on the patients’ daily 
life in order to identify subjects at risk of a sedentary life-
style and to select candidates for an intervention to promote 
physical activity.
The present study was aimed at investigating the useful-
ness of self-reported walking time to identify patients with 
COPD at high risk of inactivity. It reported and compared 
the self-reported daily walking times of a large sample of 
patients with COPD from both primary care and specialized 
respiratory departments according to the clinical characteris-
tics related to disease severity, such as the degree of airflow 
limitation, the grade of dyspnea, and different multidimen-
sional scoring systems.
Methods
study design, participants, and ethics
A pooled analysis of individual-level data from four mul-
ticenter, cross-sectional, observational studies described 
elsewhere was performed: the INSEPOC (Spanish acronym 
for “Impact of socio-economic status on quality of life of 
COPD patients”),11 the FYCEPOC (Spanish acronym for 
“Phenotypes and quality of life of patients with COPD”),12 the 
NEREA (Spanish acronym for “New severity scale for COPD 
in primary care”),13 and the DEPREPOC (Spanish acronym 
for “Depression in patients with COPD”)14 studies. In brief, 
stable COPD patients were recruited from both primary 
care and pulmonology departments. All the studies included 
individuals aged $40 years, smokers or ex-smokers of at 
least 10 pack-years with spirometrically confirmed COPD 
(post-bronchodilator forced expiratory volume in the first 
second [FEV
1
]/forced vital capacity ,0.7). All the studies 
were approved by the Research and Ethics Committee of the 
Hospital Clinic (Barcelona, Spain), and written informed 
consent was obtained from each participant.
Measurements
Physical activity defined as patients’ self-reported daily 
walking time was collected in a personal interview, and 
patients were classified into three categories of physical 
activity: low (self-reported walking time ,30 min/day), 
moderate (self-reported walking time of 30–60 min/day), and 
high (self-reported walking time .60 min/day). Self-reported 
daily walking time both as a continuous and as a categorical 
variable was used in the analysis.
Sociodemographic, clinical, and functional data as well 
as the number of exacerbations and hospital admissions 
due to COPD in the previous year were collected from all 
of the patients studied. Forced spirometry was conducted 
before and after a bronchodilator test, and self-reported 
comorbid conditions were calculated according to the 
Charlson comorbidity index.15 Dyspnea was assessed using 
the modified Medical Research Council (mMRC) dyspnea 
scale16 in three studies,12–14 and the COPD assessment test 
(CAT) score17 was available in two of the studies.12–14 
Higher values in the CAT questionnaire indicate worse 
health status.17
Patients were classified according to the FEV
1
 as 
mild, moderate, severe, and very severe following the 
European Respiratory Society and the American Thoracic 
Society (ERS/ATS) criteria18 as well as the current Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
A to D groups, using the highest mMRC or CAT thresholds.1 
According to this classification, patients in GOLD B and D 
have higher symptom scores in common. The BODEx (body 
mass index, airway obstruction, dyspnea, and exacerbation) 
index, with which higher values indicate poor prognosis, was 
also calculated accordingly.19
statistical analysis
Descriptive data are presented as number and percentage, 
and the mean and standard deviation (SD), or the median 
and 25th or 75th percentiles, as appropriate. Self-reported 
walking time, both as a continuous and as a categorical 
variable, was described and compared according to various 
disease severity markers. A test for trends was calculated by 
using various disease severity markers as an ordinal variable 
in a linear regression model and the self-reported walking 
time as a continuous outcome. Finally, bivariate logistic 
regression models were used to calculate pooled odds 
ratios (ORs) for self-reported walking time ,30 min/day 
according to disease severity markers. The analyses were 
performed by using Stata 12.1 (StataCorp, College Station, 
TX, USA).
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Results
Information related to the self-reported daily walking time 
was available in 5,969 patients. Table 1 presents the main 
clinical and functional characteristics of the pooled sample. 
Most of the patients studied were males (86%) with a mean 
age of 67.5 (SD 9.6) years and a FEV
1
 of 50.7% (17.2) pre-
dicted. Regarding GOLD groups, the majority of patients 
(73%) belonged to the GOLD D group.
Patients reported a mean daily walking time of 66 
(SD 47) min/day, with 893 (15.0%) patients being clas-
sified as physically inactive (self-reported daily walking 
time ,30 min/day) (Figure 1). Table 2 shows the self-
reported daily walking times according to different charac-
teristics related to disease severity.
A linear dose–response relationship was observed between 
the self-reported daily walking time as a continuous variable 
and the mMRC dyspnea score, COPD admissions within 
the previous year, the CAT score, the BODEx index, and 
the Charlson index (P,0.001). That is, lower walking times 
were associated with worse markers of disease severity. Self-
reported daily walking times were lower in patients classified 
as GOLD B and D than those in the GOLD A and C groups 
(P,0.001). There was no dose–response relationship between 
self-reported daily walking time and FEV
1
 levels (P=0.080) 
(Figure 2). Figure 3 shows the distribution of patients with 
low, moderate, and high self-reported daily walking times 
according to different markers of disease severity. Low physi-
cal activity was more frequent in patients with severe dyspnea 
(mMRC $3), more than two COPD admissions in the previous 
12 months, CAT score .30, and BODEx index .4 points.
Table 3 shows the ORs for lower self-reported daily 
walking times according to different COPD severity factors. 
Patients at a higher risk of low self-reported daily physical 
activity were those with mMRC or Charlson index .3, a 
FEV
1
 ,30% predicted, at least one COPD admission in the 
previous year, classified as GOLD B or D, a BODEx .4, 
and CAT score .30.
Discussion
The present study investigated the relationship between 
self-reported daily walking time and relevant characteris-
tics related to COPD severity in a large sample of patients 
Table 1 sociodemographic, clinical, and functional characteristics of the patients included in different studies
Parameter All# n=5,969 INSEPOC n=2,026 FYCEPOC n=2,735 NEREA n=622 DEPREPOC n=586
age (years) 67.5 (9.6) 67.4 (9.6) 67.0 (9.6) 68.8 (10.0) 68.8 (9.1)
sex (male) 5,145 (86.3) 1,831 (90.4) 2,273 (83.1) 546 (87.9) 495 (85.1)
active smokers 1,394 (23.4) 534 (26.5) 616 (23.7) 126 (20.7) 118 (20.31)
Body mass index (kg/m2) 27.8 (4.4) 27.9 (4.4) 27.7 (4.3) 27.7 (4.1) 27.5 (4.6)
Comorbidities (Charlson index) 2 (1–3) 2 (1–3) 2 (1–2) 2 (1–3) 2 (1–3)
mMrC (n=3,937)
0 246 (6.3) – 170 (6.2) 51 (8.3) 25 (4.2)
1 1533 (38.9) – 1,027 (37.5) 299 (48.4) 207 (35.4)
2 1373 (34.9) – 987 (36.1) 159 (25.8) 227 (38.8)
3 665 (16.9) – 459 (16.8) 88 (14.3) 118 (20.2)
4 120 (3.0) – 92 (3.4) 20 (3.2) 8 (1.4)
ambulatory COPD exacerbation¶ 1 (0–2) 2 (1–3) 1 (0–2) 1 (1–2) 2 (1–3)
COPD admissions¶ 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 1 (0–2)
FeV1 (% predicted) 50.7 (17.2) 47.7 (16.2) 51.9 (17.9) 52.8 (15.9) 52.8 (16.7)
FeV1 levels
80% predicted 319 (5.3) 71 (3.5) 201 (7.4) 18 (2.9) 29 (4.9)
50% and ,80% predicted 2,634 (44.1) 784 (38.7) 1,225 (44.8) 325 (52.3) 300 (51.2)
30% and ,50% predicted 2,315 (38.8) 878 (43.3) 1,002 (36.6) 226 (36.3) 209 (35.7)
,30% predicted 701 (11.7) 293 (14.5) 307 (11.2) 53 (8.5) 48 (8.2)
gOlD groups (n=3,209)
a 156 (4.9) – 141 (5.3) – 15 (2.8)
B 542 (16.9) – 491 (18.3) – 51 (9.7)
C 168 (5.2) – 146 (5.5) – 22 (4.2)
D 2,343 (73.0) – 1,903 (70.9) – 440 (83.3)
BODex index (n=3,765) 2 (1–4) – 2 (1–4) 2 (1–4) 3 (2–4)
CaT (n=3,262) 20.0 (8.3) – 19.2 (8.2) – 21.2 (8.1)
Notes: Data are presented as n (%), mean (sD), or median (percentile 25–p75). #some variables have missing values: 27 in age, 9 in sex, 169 in active smoker, 54 in body 
mass index, 165 in ambulatory COPD exacerbation, and 135 in COPD admissions. ¶number of events in the previous 12 months.
Abbreviations: BODex, body mass index, airway obstruction, dyspnea, exacerbation; CaT, COPD assessment test; DePrePOC, Depression in patients with COPD; 
FeV1, forced expiratory volume in the first second; FYCEPOC, Phenotypes and quality of life of patients with COPD; GOLD, Global Initiative for Chronic Obstructive Lung 
Disease; INSEPOC, Impact of socio-economic status on quality of life of COPD patients; mMRC, modified Medical Research Council dyspnea score; NEREA, New severity 
scale for COPD in primary care; sD, standard deviation.





Figure 1 Distribution of self-reported daily walking times in the 5,969 COPD study patients.
Abbreviation: COPD, chronic obstructive pulmonary disease.
Table 2 self-reported daily walking time according to different characteristics related to disease severity
Characteristics Patients (n) Self-reported daily walking time (min/day)
Mean (SD) ,30 min/day n (%) $30 min/day n (%)
mMrC dyspnea score
0–1 1,779 73 (46) 161 (9.1) 1,618 (90.9)
2 1,373 61 (42) 181 (13.2) 1,192 (86.8)
3 665 48 (40) 187 (28.1) 478 (71.9)
4 120 25 (29) 77 (64.2) 43 (35.8)
FeV1 levels
80% predicted 319 64 (47) 48 (15.1) 271 (84.9)
50% and ,80% predicted 2,634 68 (47) 306 (11.6) 2,328 (88.4)
30% and ,50% predicted 2,315 64 (46) 381 (16.4) 1,934 (83.6)
,30% predicted 701 60 (47) 158 (22.5) 543 (77.5)
COPD admissions¶ 
0 3,457 71 (48) 398 (11.4) 3,063 (88.6)
1 1,288 63 (46) 198 (15.4) 1,090 (84.6)
2 598 55 (44) 144 (24.1) 454 (75.9)
.2 491 49 (41) 142 (28.9) 349 (71.1)
CaT
,10 522 76 (48) 41 (7.8) 481 (92.2)
10–20 1,212 66 (43) 148 (12.2) 1,064 (87.8)
20–30 1,224 56 (39) 239 (19.5) 985 (80.5)
.30 304 44 (38) 94 (30.9) 210 (69.1)
gOlD groups
a 156 80 (49) 8 (5.1) 148 (94.9)
B 542 64 (42) 66 (12.2) 476 (87.8)
C 168 79 (50) 13 (7.7) 155 (92.3)
D 2,343 58 (42) 431 (18.4) 1,912 (81.6)
BODex index
0–1 1,082 70 (44) 87 (8.0) 995 (92.0)
2 821 67 (45) 103 (12.6) 718 (87.4)
3–4 1,180 61 (45) 186 (15.8) 994 (84.2)
.4 682 48 (41) 209 (30.7) 473 (69.3)
Charlson index
1 2,302 69 (48) 283 (12.3) 2,019 (87.7)
2 2,045 67 (46) 283 (13.8) 1,762 (86.2)
3 1,080 60 (44) 185 (17.1) 895 (82.9)
4 542 55 (47) 142 (26.2) 400 (73.8)
Note: ¶number of events in the previous 12 months.
Abbreviations: BODex, body mass index, airway obstruction, dyspnea, exacerbation; CaT, COPD assessment test; COPD, chronic obstructive pulmonary disease; FeV1, 
forced expiratory volume in the first second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council dyspnea scale; SD, 
standard deviation.
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Figure 2 self-reported daily walking times according to (A) mMrC, (B) FeV1% predicted, (C) COPD admissions in the previous 12 months, (D) CaT, (E) gOlD a–D 
groups, (F) BODex index, and (G) Charlson index of comorbidities. Data are presented as mean values with 95% confidence intervals.
Abbreviations: BODex, body mass index, airway obstruction, dyspnea, exacerbation; CaT, COPD assessment test; COPD, chronic obstructive pulmonary disease; FeV1, 
forced expiratory volume in the first second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council dyspnea scale.
with COPD. The main findings were that patients reporting 
lower walking times were those with more dyspnea, more 
comorbidities, higher BODEx index, patients classified as 
GOLD B or D and with previous hospitalizations due to 
COPD exacerbation. Furthermore, airflow limitation was 
poorly related to self-reported daily walking time.
Most patients with COPD spend significantly less 
time walking in daily life than healthy elderly subjects.3,20 





Figure 3 Percentage of patients with self-reported walking time ,30 min/day ( ), between 30 and 60 min/day ( ), and .60 min/day ( ) according to (A) mMrC, (B) 
FeV1% predicted, (C) COPD admissions in the previous 12 months, (D) CaT, (E) gOlD a–D groups, (F) BODex index, and (G) Charlson index of comorbidities.
Abbreviations: BODex, body mass index, airway obstruction, dyspnea, exacerbation; CaT, COPD assessment test; COPD, chronic obstructive pulmonary disease; FeV1, 
forced expiratory volume in the first second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council dyspnea scale.
Low physical activity is a marker of poor health outcomes in 
COPD,4,6 and thus, it is important to detect COPD patients at 
risk in order to implement specific interventions to prevent 
inactivity. The use of activity monitors and comprehensive 
questionnaires to capture physical activity is not feasible in 
routine clinical practice. Therefore, the utility of a simple 
clinical measure to predict inactivity in COPD was deter-
mined: patients’ self-reported daily walking time. The rela-
tionship between self-reported walking time and a number of 
markers of severity routinely used in the clinical management 
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Table 3 Ors for the determinants of reduced self-reported 
walking time
Determinant OR for self-reported 





2 1.86 (1.57–2.20) ,0.001
3 3.57 (2.92–4.37) ,0.001
4 16.35 (11.07–24.13) ,0.001
FeV1 levels
80% predicted 1.00
50% and ,80% predicted 0.74 (0.53–1.03) 0.080
30% and ,50% predicted 1.11 (0.80–1.54) 0.522
,30% predicted 1.64 (1.15–2.34) 0.006
COPD admissions¶ 
0 1.00
1 1.41 (1.17–1.70) ,0.001
2 2.47 (1.99–3.06) ,0.001
.2 3.16 (2.53–3.95) ,0.001
CaT
,10 1.00
10–20 1.63 (1.14–2.34)  0.008
20–30 2.85 (2.01–4.03) ,0.001
.30 5.25 (3.52–7.84) ,0.001
gOlD groups
a 1.00
B 2.57 (1.20–5.47)  0.015
C 1.55 (0.63–3.85)  0.344
D 4.17 (2.03–8.56) ,0.001
BODex index
0–1 1.00
2 1.52 (1.19–1.93)  0.001
3–4 2.10 (1.70–2.60) ,0.001
.4 5.08 (4.06–6.37) ,0.001
Charlson index
1 1.00
2 1.15 (0.96–1.37) 0.131
3 1.47 (1.21–1.80) ,0.001
4 2.53 (2.01–3.18) ,0.001
Note: ¶number of events in the previous 12 months.
Abbreviations: 95% CI, 95% confidence interval; BODEx, body mass index, airway 
obstruction, dyspnea, exacerbation; CaT, COPD assessment test; COPD, chronic 
obstructive pulmonary disease; FeV1, forced expiratory volume in the first second; 
GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified 
Medical research Council dyspnea scale; Or, odds ratio.
of patients with COPD. The findings of this study indicate 
a very consistent association between self-reported walking 
time and known parameters of COPD severity. Moreover, 
the results are in line with previous research conducted in 
this field using objective measures of physical activity, such 
as pedometers and accelerometers.21–24 Therefore, although it 
is unlikely for the simple question of “on average how many 
minutes do you walk per day?” to be an accurate measure of 
physical activity, it may be a useful tool to stratify COPD 
patients according to their level of physical activity in the 
clinical setting. Asking about the number of minutes walked 
per day is inexpensive and not time-consuming and provides 
important information to help screen patients with low physi-
cal activity that can be confirmed by more specific methods. 
The use of this simple question may increase the awareness of 
clinicians of the importance of assessing the level of physical 
activity of the patients with COPD.25
In this study, 15% of the patients were classified as physi-
cally inactive (self-reported walking times ,30 min/day). 
This percentage might be considered low compared with 
previous studies quantifying daily walking time in COPD3 but 
may be due to differences in the characteristics of the COPD 
patient samples studied, differences in localization and cli-
mate that have been reported to affect physical activity,26 and 
the instrument used to capture walking time (eg, self-reported 
methods have the potential to overestimate the amount of 
physical activity performed),8,27 among others.
In agreement with previous cross-sectional studies using 
both direct22,23,28 and indirect29,30 measures of physical activ-
ity, a strong association between self-reported walking time 
and dyspnea measured by the mMRC in the COPD patients 
was found. Indeed, the mMRC dyspnea score was the best 
factor to detect patients with lower walking times. COPD 
is characterized by symptoms of dyspnea, cough, wheeze, 
and sputum production.1 Dyspnea is a particularly dominant 
symptom in these patients, especially as the disease advances, 
and usually limits patient mobility.31 Indeed, dyspnea is the 
reason most frequently reported to prevent patients from 
exercising,29,32 further supporting our findings. Although 
dyspnea measured by mMRC is significantly related to 
self-reported walking time in this study, different aspects of 
the impact of the disease are, in fact, measured. Thus, these 
parameters should not be used interchangeably.
In addition, exacerbations requiring hospitalization within 
the previous 12 months and comorbidities were related to 
lower walking times in the patients. Several studies have 
shown that exacerbations have a negative impact on health 
outcomes of patients with COPD, impairing lung function,33 
quality of life,34 exercise capacity,35 and survival.36 Along this 
line, a fall in daily walking activity following an exacerbation 
has been reported using pedometry in COPD.21 Since bed rest 
and physical inactivity following exacerbation periods impair 
skeletal muscle mass and function,37 it is not surprising that 
patients presenting the most severe exacerbations are those 
who are less active.
Accordingly, other markers of disease severity such as 
the GOLD A–D classification, the BODEx index, and the 





CAT score which include dyspnea and exacerbation in their 
calculation were also related to the self-reported walking time 
in this study. Similar results have been previously reported 
by using direct measures of physical activity.24
This study found airflow limitation to be poorly related to 
self-reported walking time. Although in some previous stud-
ies, FEV
1
 has shown a weak–moderate association with objec-
tively measured physical activity in patients with COPD,3,22 
other studies have not observed this relationship.38–40 In 
general, FEV
1
 is known to explain only a small proportion 
of the variation in physical activity in subjects with COPD 
as physical activity is dependent on many factors, including 
biological, behavioral, social, and environmental factors, 
among others.7 Therefore, we should go beyond FEV
1
 to bet-
ter understand how the disease affects the COPD patients.
The main strengths of this study include the large sample 
of COPD patients with a large variability of disease severity, 
the different clinical settings in which the patients were tested 
(primary care and specialized pneumology departments), and 
the wide range of outcome variables used in this analysis. 
However, the results of this study may be affected by several 
limitations. First, an indirect measure of physical activity 
(patient self-reported walking time) was used, which may 
be inaccurate, does not quantify the intensity of the activi-
ties, and does not capture other physically activities apart 
from walking. However, walking is the most common way 
of exercising in the daily life of the elderly.41 Second, the 
associations observed between self-reported walking time 
and markers of COPD severity do not mean that the ques-
tion “on average how many minutes do you walk per day?” 
is a valid measure of physical activity in each individual 
patient. This is not a formal validation study, as no objective 
measure was used to compare the results obtained; however, 
the results support the usefulness of the question to identify 
a subpopulation of patients who may require interventions to 
promote physical activity (those with self-reported walking 
times of ,30 min/day). Certainly, further studies are needed 
to validate this question as a reliable measure to identify 
inactive patients in the clinical setting. In addition, some 
of the variables tested in these analyses are included in the 
multidimensional markers of severity, and thus, adjusted 
multivariate analyses could not be performed. Third, few 
women were included; therefore, the results cannot be gen-
eralized to both the sexes. However, the studies included in 
this analysis had no exclusion criteria in relation to sex. The 
lower proportion of women reflects the COPD distribution 
by sex in this country, as previously reported.42 Finally, 
the cross-sectional nature of the study does not allow us to 
establish the direction of the observed associations.
Conclusion
Lower self-reported walking times are related to worse 
markers of disease severity routinely used in the clinical 
management of patients with COPD. The use of the question 
“on average how many minutes do you walk per day?” may 
provide a simple method for clinicians to identify physically 
inactive COPD patients.
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